SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN)
BTRN 35.400.0%Nov 28 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: trevor john wilkinson who started this subject3/27/2001 8:07:02 AM
From: Mark Bong   of 1475
 
GAITHERSBURG, Md., March 26 /PRNewswire/ -- MedImmune, Inc. (Nasdaq: MEDI)
announced today that it will present at Banc of America Securities' Healthcare
2001 Conference at 2:40 p.m. PST on Tuesday, March 27, 2001. The conference
is being held at the Four Seasons Hotel in Las Vegas, Nevada from March 27-29,
2001. MedImmune's presentation will be webcast live for investors and
available for replay for a period of 14 days following the conference at:

veracast.com

MedImmune, Inc. is a biotechnology company focused on developing and
marketing products that address medical needs in areas such as infectious
disease, immune regulation and cancer. Headquartered in Gaithersburg,
Maryland, MedImmune has manufacturing facilities in Frederick, Maryland and
Nijmegen, the Netherlands.

This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the company's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext